共 50 条
Improving Inhalation Performance with Particle Agglomeration via Combining Mechanical Dry Coating and Ultrasonic Vibration
被引:2
|作者:
Zhang, Qingzhen
[1
]
Wang, Zheng
[1
,2
]
Shi, Kaiqi
[3
]
Zhou, Hang
[4
]
Wei, Xiaoyang
[5
]
Hall, Philip
[1
,5
]
Giovagnoli, Stefano
机构:
[1] Univ Nottingham Ningbo China, Dept Chem & Environm Engn, Ningbo 315100, Peoples R China
[2] Univ Nottingham Ningbo China, Key Lab Carbonaceous Wastes Proc & Proc Intensific, Ningbo 315100, Peoples R China
[3] Suzhou Inhal Pharm Co Ltd, Suzhou 215000, Peoples R China
[4] Zhejiang Univ Technol, Coll Pharm, Hangzhou 310014, Peoples R China
[5] Univ Nottingham Ningbo China, Nottingham Ningbo China Beacons Excellence Res & I, Ningbo 315100, Peoples R China
关键词:
mechanical dry-coating;
ultrasonic vibration;
budesonide;
magnesium stearate;
inhalation;
POWDER INHALER;
LACTOSE MONOHYDRATE;
DRUG;
CORTICOSTEROIDS;
BUDESONIDE;
DELIVERY;
BEHAVIOR;
DESIGN;
SIZE;
D O I:
10.3390/pharmaceutics16010068
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Agglomerate formulations for dry powder inhalation (DPI) formed with fine particles are versatile means for the highly efficient delivery of budesonide. However, uncontrolled agglomeration induces high deposition in the upper airway, causing local side effects due to high mechanical strength, worse deagglomeration, and poor fine-particle delivery. In the present study, fine lactose was mechanically dry-coated prior to particle agglomeration, and the agglomerates were then spheroidized via ultrasonic vibration to improve their aerosol performance. The results showed that the agglomerate produced with the surface-enriched hydrophobic magnesium stearate and ultrasonic vibration demonstrated improved aerosolization properties, benefiting from their lower mechanical strength, less interactive cohesive force, and improved fine powder dispersion behavior. After dispersion utilizing a Turbuhaler (R) with a pharmaceutical cascade impactor test, a fine particle fraction (FPF) of 71.1 +/- 1.3% and an artificial throat deposition of 19.3 +/- 0.4% were achieved, suggesting the potential to improve the therapeutic outcomes of budesonide with less localized infections of the mouth and pharynx.
引用
收藏
页数:22
相关论文